Q4 EPS Estimate for Edwards Lifesciences Lifted by Analyst

Edwards Lifesciences Co. (NYSE:EW) – Analysts at Leerink Partnrs upped their Q4 2025 earnings per share estimates for Edwards Lifesciences in a report released on Wednesday, April 16th. Leerink Partnrs analyst M. Kratky now anticipates that the medical research company will post earnings of $0.64 per share for the quarter, up from their prior estimate of $0.63. The consensus estimate for Edwards Lifesciences’ current full-year earnings is $2.45 per share. Leerink Partnrs also issued estimates for Edwards Lifesciences’ FY2029 earnings at $4.19 EPS.

EW has been the subject of several other research reports. Royal Bank of Canada reaffirmed an “outperform” rating and set a $85.00 target price on shares of Edwards Lifesciences in a research note on Wednesday, February 12th. Morgan Stanley boosted their target price on Edwards Lifesciences from $70.00 to $75.00 and gave the company an “equal weight” rating in a research report on Wednesday, February 12th. Piper Sandler raised their price target on Edwards Lifesciences from $70.00 to $73.00 and gave the stock a “neutral” rating in a research report on Wednesday, February 12th. Truist Financial cut their price objective on Edwards Lifesciences from $78.00 to $75.00 and set a “hold” rating on the stock in a report on Friday, April 11th. Finally, Wolfe Research cut Edwards Lifesciences from a “hold” rating to a “strong sell” rating in a report on Wednesday, February 12th. One analyst has rated the stock with a sell rating, fourteen have given a hold rating and ten have issued a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $78.55.

Edwards Lifesciences Stock Performance

NYSE EW opened at $71.56 on Thursday. The stock has a fifty day simple moving average of $71.30 and a 200-day simple moving average of $70.80. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06. The stock has a market cap of $42.07 billion, a PE ratio of 10.27, a P/E/G ratio of 4.82 and a beta of 1.15. Edwards Lifesciences has a twelve month low of $58.93 and a twelve month high of $95.25.

Edwards Lifesciences (NYSE:EW) last posted its earnings results on Tuesday, February 11th. The medical research company reported $0.59 earnings per share for the quarter, beating the consensus estimate of $0.55 by $0.04. Edwards Lifesciences had a net margin of 72.93% and a return on equity of 19.40%.

Hedge Funds Weigh In On Edwards Lifesciences

Institutional investors have recently modified their holdings of the business. Norges Bank acquired a new position in Edwards Lifesciences in the fourth quarter valued at $610,895,000. Jennison Associates LLC acquired a new position in Edwards Lifesciences in the 4th quarter valued at about $555,939,000. Vanguard Group Inc. raised its stake in Edwards Lifesciences by 10.4% during the 4th quarter. Vanguard Group Inc. now owns 69,132,036 shares of the medical research company’s stock valued at $5,117,845,000 after acquiring an additional 6,537,494 shares during the last quarter. Assenagon Asset Management S.A. lifted its position in Edwards Lifesciences by 475.8% during the 4th quarter. Assenagon Asset Management S.A. now owns 4,243,976 shares of the medical research company’s stock worth $314,182,000 after acquiring an additional 3,506,886 shares during the period. Finally, Raymond James Financial Inc. acquired a new stake in Edwards Lifesciences during the 4th quarter worth approximately $213,844,000. 79.46% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, CFO Scott B. Ullem sold 11,250 shares of the business’s stock in a transaction dated Thursday, February 13th. The stock was sold at an average price of $75.76, for a total value of $852,300.00. Following the completion of the sale, the chief financial officer now directly owns 30,561 shares of the company’s stock, valued at approximately $2,315,301.36. The trade was a 26.91 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, VP Donald E. Bobo, Jr. sold 6,500 shares of the company’s stock in a transaction dated Thursday, February 13th. The shares were sold at an average price of $75.75, for a total value of $492,375.00. Following the completion of the sale, the vice president now directly owns 46,936 shares of the company’s stock, valued at approximately $3,555,402. This trade represents a 12.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 71,853 shares of company stock valued at $5,163,062. 1.29% of the stock is owned by corporate insiders.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.